Is Low-Molecular-Weight Heparin the Answer for the Therapy of Acute Deep Vein Thrombosis?

Abstract

Get full access to this article

View all access options for this article.

References

1. Colditz GA , Tuden RL , Oster G : Rates of venous thrombosis after general surgery: Combined results of randomized clinical trials. Lancet 2:143-143, 1986.

2. Anderson FA Jr , Wheeler HB , Goldberg RJ , et al: A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 151:933-938, 1991.

3. Market A , Manzo RA , Bergelin RO , et al: Vascular reflux after deep vein thrombosis: Incidence and time of occurrence. J Vasc Surg 15:377-382, 1992.

4. Barritt DW , Jordan SC : Anticoagulant drugs and the treatment of pulmonary embolism: A control trial. Lancet 1:1309-1312, 1960.

5. Howard PA : Dalteparin: A low-molecular-weight heparin. Ann Pharmacother 31:192-203, 1997.

6. Alhenc-Gelas M , Jestin-Le GC , Vitoux JF , et al: Adjusted versus fixed doses of the low-molecularweight heparin fragmin in the treatment of deep vein thrombosis. Fragmin Study Group. Thromb Haemost 71:698-702, 1994.

7. Van Ryn-McKenna J , Cai L , Ofosu FA , et al: Neutralization of enoxaparin-induced bleeding by protamine sulfate. Thromb Haemost 63:271-274, 1990.

8. Kitka MJ , Keller MP , Humphrey PW , et al: Can lowmolecular-weight heparins and heparinoids be safely given with heparin-induced thrombocytopenia syndrome? Surgery 114:705-710, 1993.

9. Prandoni P , Lensing AW , Buller HR , et al: Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 339:441-445, 1992.

10.

10. Hull RD , Raskob GE , Pineo GF , et al: Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 326:975-982, 1992.

11.

11. Levine M , Gent M , Hirsh J , et al: A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 334:677-681, 1996.

12.

12. Koopman MM , Prandoni P , Piovella F , et al: Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 334:682-687, 1996.

13.

13. The Columbus Investigators . Low molecular weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 337:657-662, 1997.

14.

14. Simonneau G , Sors H , Charbonnier B , et al: A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. N Engl J Med 337:663-669, 1997.

15.

15. Hawkins DW , Langley PC , Krueger KP : Pharmacoeconomic model of enoxaparin versus heparin for prevention of deep vein thrombosis after total hip replacement. Am J Health-Syst Pharm 54:1185-1190, 1997.

16.

16. Dedden P , Chang B , Nagel D : Pharmacy-managed program for home treatment of deep vein thrombosis with enoxaparin. Am J Heath-Syst Pharm 54:1968-1972, 1997.

17.

17. Fejgin MD , Lourwood DL : Low-molecular-weight heparins and their use in obstetrics and gynecology. Obstet Gynecol Surv 49:424-431, 1994.

18.

18. Gillis S , Sushan A , Elder A : Use of low molecular weight heparin for prophylaxis and treatment of thromboembolism in pregnancy. Int J Gynaecol Obstet 39:297-301, 1992.